Dear Colleague:

Over the last five years, Cambridge Healthtech Institute’s Biomarker Series has become the premier producer of cutting-edge meetings focusing on biomarker discovery and implementation.

This year, we are pleased to return to Vienna for our Second Annual Biomarkers Europe meeting. The comprehensive pro-gram covers biomarker implementation in early clinical trials, safety assessment and clinical pharmacology, and personalized medicine, as well as biomarker validation, both from the biological and analytical perspectives. Drawing on presentations from GlaxoSmithKline, AstraZeneca, Bayer Healthcare, Eli Lilly, F. Hoffmann-La Roche, Boehringer Ingelheim, Pfizer, Johnson & Johnson, and more, the program brings the best examples and case studies in biomarker implementation.

I look forward to seeing you in Vienna!

Julia Boguslavsky
Conference Director, The Biomarker Series
Cambridge Healthtech Institute
Email: juliab@healthtech.com